Sutro Biopharma (NASDAQ:STRO) Rating Reiterated by JMP Securities

Sutro Biopharma (NASDAQ:STRO)‘s stock had its “market outperform” rating reissued by stock analysts at JMP Securities in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $17.00 price objective on the stock. JMP Securities’ price target points to a potential upside of 244.83% from the stock’s current price.

Several other equities analysts also recently weighed in on STRO. HC Wainwright cut their target price on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Sutro Biopharma in a research report on Friday, January 5th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Sutro Biopharma currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Sutro Biopharma Trading Up 17.9 %

Shares of STRO stock opened at $4.93 on Tuesday. The stock’s 50-day moving average price is $4.47 and its 200-day moving average price is $3.77. Sutro Biopharma has a 12-month low of $2.01 and a 12-month high of $6.11. The stock has a market capitalization of $300.48 million, a price-to-earnings ratio of -2.77 and a beta of 0.95.

Insider Activity at Sutro Biopharma

In other news, insider Nicki Vasquez sold 12,185 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $5.00, for a total value of $60,925.00. Following the sale, the insider now directly owns 12,803 shares of the company’s stock, valued at approximately $64,015. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Sutro Biopharma by 331.7% in the 4th quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock valued at $46,000 after purchasing an additional 4,372 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Sutro Biopharma in the first quarter valued at approximately $56,000. Nisa Investment Advisors LLC raised its stake in shares of Sutro Biopharma by 14,125.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock worth $38,000 after buying an additional 8,758 shares during the period. Point72 Hong Kong Ltd purchased a new position in shares of Sutro Biopharma during the 2nd quarter valued at approximately $46,000. Finally, Quantbot Technologies LP grew its stake in Sutro Biopharma by 117.1% in the 1st quarter. Quantbot Technologies LP now owns 8,900 shares of the company’s stock valued at $73,000 after acquiring an additional 4,800 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.